- Home
- RCG vs AIM Comparison
RCG vs AIM Comparison
Compare RCG & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- AIM
- Stock Information
- Founded
- RCG 1994
- AIM 1966
- Country
- RCG United States
- AIM United States
- Employees
- RCG N/A
- AIM N/A
- Industry
- RCG Investment Managers
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCG Finance
- AIM Health Care
- Exchange
- RCG Nasdaq
- AIM Nasdaq
- Market Cap
- RCG 15.6M
- AIM 15.9M
- IPO Year
- RCG N/A
- AIM N/A
- Fundamental
- Price
- RCG $2.87
- AIM $0.23
- Analyst Decision
- RCG
- AIM Strong Buy
- Analyst Count
- RCG 0
- AIM 2
- Target Price
- RCG N/A
- AIM $2.75
- AVG Volume (30 Days)
- RCG 5.9K
- AIM 670.8K
- Earning Date
- RCG 01-01-0001
- AIM 11-15-2024
- Dividend Yield
- RCG 0.98%
- AIM N/A
- EPS Growth
- RCG N/A
- AIM N/A
- EPS
- RCG N/A
- AIM N/A
- Revenue
- RCG N/A
- AIM $190,000.00
- Revenue This Year
- RCG N/A
- AIM N/A
- Revenue Next Year
- RCG N/A
- AIM $1,693.10
- P/E Ratio
- RCG N/A
- AIM N/A
- Revenue Growth
- RCG N/A
- AIM N/A
- 52 Week Low
- RCG $1.52
- AIM $0.16
- 52 Week High
- RCG $1.90
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- RCG 65.66
- AIM 56.35
- Support Level
- RCG $2.32
- AIM $0.19
- Resistance Level
- RCG $2.58
- AIM $0.23
- Average True Range (ATR)
- RCG 0.12
- AIM 0.02
- MACD
- RCG 0.04
- AIM 0.00
- Stochastic Oscillator
- RCG 100.00
- AIM 68.43
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.